A phase I study of KITE-585 for the treatment of multiple myeloma

Trial Profile

A phase I study of KITE-585 for the treatment of multiple myeloma

Planning
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs KITE 585 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 08 Aug 2017 According to a Kite Pharma media release, the company expects to initiate this study in the second half of 2017.
    • 08 Aug 2017 According to a Kite Pharma Inc. media release, the company submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1, first-in-human trial of KITE-585 in patients with relapsed/refractory multiple myeloma.
    • 04 Apr 2017 According to a Kite Pharma media release, the company expects to initiate this study in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top